CGRP Education & Research Forum
Already a member? Become a member Register
IHC 2019

Join us now

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

View invitations from the editors
Become a member of CGRP Forum now

Migraine: a new treatment landscape

As clinicians witness a revolution in thinking about migraine and its treatment, Peter Goadsby considers how the future availability of CGRP monoclonal antibodies and small molecule gepants will change the treatment landscape. He welcomes the growing opportunities for patients to be offered individualised treatment that enables them to take back control of their lives.

Why is CGRP an important therapeutic target?

Multiple lines of evidence support a role for CGRP in migraine pathophysiology.

Its blockade is now a potentially important therapeutic target for migraine prevention.

Read more Become a member

Is anti-CGRP therapy approved for your patients?

Take a look at our new expert guide to the regulatory status and approved indications for anti-CGRP therapies worldwide.

Read More
From the Editors
Our distinguished Editors discuss the latest developments and provide their views:Will CGRP antibodies put an end to migraine?View all articles
Members get free, open access - Register now »
Easy-to-access digests of all the key trials completed & ongoing:Eptinezumab (ALD403)Erenumab (AMG 334)Galcanezumab (LY2951742)Fremanezumab (TEV-48125)View all Trials